Equity Profile

RDY

Dr. Reddy's Laboratories Limited

Health CarePharmaceuticals$10.8B

May12Tue

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Dr. Reddy's Laboratories Limited is a pharmaceutical company based in India, focusing on producing generic medications and active pharmaceutical ingredients....

Key Metrics to Watch

Revenue Growth

This metric indicates how well the company is expanding its sales, which is crucial for assessing overall business health.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and is closely watched by investors.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RDY Q4-2026 Earnings Preview

Context

Company Snapshot

Dr. Reddy's Laboratories Limited is a pharmaceutical company based in India, focusing on producing generic medications and active pharmaceutical ingredients. With a market cap of $11 billion, it plays a significant role in the healthcare sector, especially as demand for affordable medications continues to grow globally.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

+0.00%

Avg Stock Reaction

-2.67%

Last Quarter Recap

In the last quarter, Dr. Reddy's continued to face challenges in the competitive pharmaceutical landscape, but it also made strides in expanding its product offerings. The company did not provide specific guidance, leaving investors uncertain about future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious ahead of the earnings report, given the lack of recent guidance and mixed historical performance. The market is looking for signs of growth and stability in a challenging environment.

Bull Case

If Dr. Reddy's can demonstrate strong revenue growth and improved profitability, it could signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company reports disappointing earnings or weak guidance, it may lead to further declines in stock price, reflecting ongoing market challenges.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is critical for assessing the company's ability to compete in the pharmaceutical market and meet investor expectations.

How is Dr. Reddy's managing its market share in the generics segment?

Market share insights will help investors understand the company's competitive position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Dr. Reddy's ability to capture market share in the generics sector, especially given recent trends in healthcare spending.

Supporting Evidence

Options are pricing in an 8.11% move, indicating higher volatility expectations than historical performance suggests.

The company's recent product launches may not be fully reflected in current market expectations.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious sentiment and shift investor perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Dr. Reddy's ability to navigate a competitive landscape while maintaining or growing its market share.

Bull Confirmed If

Demonstrating revenue growth of over 10% year-over-year would confirm the bull case.

Bear Confirmed If

If revenue growth is below 3%, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.11%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±8.1% while RDY has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

30d HV

31.2%

Calls (33K)P/C Ratio: 0.00Puts (100)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

13.94%

of float

Insider

0.00%

of float

Holders

323

institutions

Top Holders· as of Mar 2026

Robeco Institutional Asset Management B.V.
17,177,882 sh · $234.8M
2.06%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dr. Reddy's beats expectations, history suggests the stock could rise by around 5.5%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to a muted response, as investors weigh the implications of management's commentary.

Miss

If the company misses expectations, history indicates a potential decline of about 8%, reflecting ongoing concerns in the market.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into cost management strategies and their effect on profitability.
3Details on market share changes in the generics segment.
4Management's outlook on the competitive landscape in pharmaceuticals.
5Any commentary on regulatory challenges or opportunities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

RadNet, Inc.

Company Snapshot

Dr. Reddy's Laboratories Limited is a pharmaceutical company based in India, focusing on producing generic medications and active pharmaceutical ingredients....

Key Metrics to Watch

Revenue Growth

This metric indicates how well the company is expanding its sales, which is crucial for assessing overall business health.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and is closely watched by investors.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RDY Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

+0.00%

Avg Stock Reaction

-2.67%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Dr. Reddy's can demonstrate strong revenue growth and improved profitability, it could signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company reports disappointing earnings or weak guidance, it may lead to further declines in stock price, reflecting ongoing market challenges.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth is critical for assessing the company's ability to compete in the pharmaceutical market and meet investor expectations.

How is Dr. Reddy's managing its market share in the generics segment?

Market share insights will help investors understand the company's competitive position and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Dr. Reddy's ability to capture market share in the generics sector, especially given recent trends in healthcare spending.

Supporting Evidence

Options are pricing in an 8.11% move, indicating higher volatility expectations than historical performance suggests.

The company's recent product launches may not be fully reflected in current market expectations.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious sentiment and shift investor perception.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Dr. Reddy's ability to navigate a competitive landscape while maintaining or growing its market share.

Bull Confirmed If

Demonstrating revenue growth of over 10% year-over-year would confirm the bull case.

Bear Confirmed If

If revenue growth is below 3%, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.11%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±8.1% while RDY has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

30d HV

31.2%

Calls (33K)P/C Ratio: 0.00Puts (100)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

13.94%

of float

Insider

0.00%

of float

Holders

323

institutions

Top Holders· as of Mar 2026

Robeco Institutional Asset Management B.V.
17,177,882 sh · $234.8M
2.06%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dr. Reddy's beats expectations, history suggests the stock could rise by around 5.5%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to a muted response, as investors weigh the implications of management's commentary.

Miss

If the company misses expectations, history indicates a potential decline of about 8%, reflecting ongoing concerns in the market.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into cost management strategies and their effect on profitability.
3Details on market share changes in the generics segment.
4Management's outlook on the competitive landscape in pharmaceuticals.
5Any commentary on regulatory challenges or opportunities.